The coagulation analyzers market is projected to reach USD 4.84 billion by 2021 from USD 2.98 billion in 2016, at a CAGR of 10.2% from 2016 to 2021.
The coagulation analyzers market is consolidated in nature due to the presence of a few large players. The prominent players in the coagulation analyzers market include are Siemens AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Sysmex Corporation (Japan), Nihon Kohden Corporation (Japan), Diagnostica Stago (France), Helena Laboratories (U.S.), Instrumentation Laboratory (U.S.), and International Technidyne Corporation (U.S.).
Siemens AG was the largest player in the global coagulation analyzers market, with a share of 24.7% in 2015. The company has a strong presence in the U.S. and in regions such as Europe and Asia-Pacific. It focuses on product launches and agreements as its key growth strategies. In August 2016, Siemens launched the Sysmex CS-2500 System, a new mid-volume coagulation analyzer. Moreover, in April 2016, Siemens and Sysmex extended their long-standing global agreement in hemostasis testing. This agreement allows laboratory customers around the world to continue to benefit from the largest portfolio of hemostasis systems and reagents. These developments significantly impacted the company's revenue and customer base.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197226392
Thermo Fisher Scientific, Inc. (U.S.) was the second-largest player in the coagulation analyzers market, with a market share of 13.3% in 2015. The company operates in over 50 countries across North America, Europe, Asia, and Latin America. The company pursues the strategies of agreements and expansions in order to increase its share in the coagulation analyzers market. For instance, in October 2014, Thermo Fisher Scientific established a 350,000-square-foot manufacturing facility in California, U.S. This expansion enabled the company to provide a stable supply of reagents in the U.S. Moreover, in April 2014, Thermo Fisher Scientific and the National University of Singapore (NUS) signed a memorandum of understanding. This MOU aimed to develop a strategic alliance for advance basic and applied research in Singapore.
Roche Diagnostics (Switzerland) held the third position in the global coagulation analyzers market, accounting for a market share of 12.0% in 2015. The company focuses on introducing innovative and technologically advanced products in the market. For instance, in August 2016, Roche launched the Accu-Chek Guide blood glucose monitoring system. The system offers a new spill-resistant smartpack vial and a unique strip design with a large easy-edge dosing area. This launch helped the company strengthen its market position globally.
The key strategies followed by most companies in the coagulation analyzers market are new product launches, expansions, acquisitions, agreements account for largest share of the overall growth strategies mapped from 2012 to 2016. Some of the leading players that adopted this strategy include Siemens AG (Germany), Roche Diagnostics (Switzerland), Sysmex Corporation (Japan), Diagnostica Stago (France), and Instrumentation Laboratory (U.S.)
The coagulation analyzers market is consolidated in nature due to the presence of a few large players. The prominent players in the coagulation analyzers market include are Siemens AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Sysmex Corporation (Japan), Nihon Kohden Corporation (Japan), Diagnostica Stago (France), Helena Laboratories (U.S.), Instrumentation Laboratory (U.S.), and International Technidyne Corporation (U.S.).
Siemens AG was the largest player in the global coagulation analyzers market, with a share of 24.7% in 2015. The company has a strong presence in the U.S. and in regions such as Europe and Asia-Pacific. It focuses on product launches and agreements as its key growth strategies. In August 2016, Siemens launched the Sysmex CS-2500 System, a new mid-volume coagulation analyzer. Moreover, in April 2016, Siemens and Sysmex extended their long-standing global agreement in hemostasis testing. This agreement allows laboratory customers around the world to continue to benefit from the largest portfolio of hemostasis systems and reagents. These developments significantly impacted the company's revenue and customer base.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197226392
Thermo Fisher Scientific, Inc. (U.S.) was the second-largest player in the coagulation analyzers market, with a market share of 13.3% in 2015. The company operates in over 50 countries across North America, Europe, Asia, and Latin America. The company pursues the strategies of agreements and expansions in order to increase its share in the coagulation analyzers market. For instance, in October 2014, Thermo Fisher Scientific established a 350,000-square-foot manufacturing facility in California, U.S. This expansion enabled the company to provide a stable supply of reagents in the U.S. Moreover, in April 2014, Thermo Fisher Scientific and the National University of Singapore (NUS) signed a memorandum of understanding. This MOU aimed to develop a strategic alliance for advance basic and applied research in Singapore.
Roche Diagnostics (Switzerland) held the third position in the global coagulation analyzers market, accounting for a market share of 12.0% in 2015. The company focuses on introducing innovative and technologically advanced products in the market. For instance, in August 2016, Roche launched the Accu-Chek Guide blood glucose monitoring system. The system offers a new spill-resistant smartpack vial and a unique strip design with a large easy-edge dosing area. This launch helped the company strengthen its market position globally.
The key strategies followed by most companies in the coagulation analyzers market are new product launches, expansions, acquisitions, agreements account for largest share of the overall growth strategies mapped from 2012 to 2016. Some of the leading players that adopted this strategy include Siemens AG (Germany), Roche Diagnostics (Switzerland), Sysmex Corporation (Japan), Diagnostica Stago (France), and Instrumentation Laboratory (U.S.)
No comments:
Post a Comment